Fortress Biotech, Inc. (FBIOP) Net Margin (2015 - 2026)
Fortress Biotech (FBIOP) posted quarterly Net Margin of 44.1% for Q4 2025, up 1957.0% year-over-year from 2.14% in Q4 2024, and down 311.55% quarter-over-quarter from 20.84% in Q3 2025.
Fortress Biotech, Inc. (FBIOP) Net Margin (2015 - 2026) Analysis & Trends
Fortress Biotech's Net Margin history runs 11 years deep, the most recent figure standing at 44.1% for Q4 2025.
- In Q4 2025, Net Margin rose 1957.0% year-over-year to 44.1%; the TTM figure through Dec 2025 stood at 3.15% (up 9369.0% YoY), while the FY2025 annual figure was 3.07%, up 9383.0% from the prior year.
- Net Margin for Q4 2025 stood at 44.1%, down from 20.84% in the prior quarter.
- The five-year high for Net Margin was 88.98% in Q2 2025, with the low at 29336.13% in Q2 2021.
- The 5-year median for Net Margin is 115.47% (2022), against an average of 3418.84%.
- The sharpest annual moves came in 2021 and 2022: Net Margin slumped 2903879 bps in 2021, then jumped 2920800 bps in 2022.
- Fortress Biotech's Net Margin stood at 102.34% in 2021, then jumped by 149 bps to 50.4% in 2022, then tumbled by 247 bps to 73.98% in 2023, then increased by 14 bps to 63.66% in 2024, then surged by 31 bps to 44.1% in 2025.
- Business Quant data shows FBIOP's Net Margin at 44.1% in Q4 2025, 20.84% in Q3 2025, and 88.98% in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.23% |
| Dec 31, 2025 | -44.10% |
| Sep 30, 2025 | 20.84% |
| Jun 30, 2025 | 88.98% |
| Mar 31, 2025 | -96.77% |
| Dec 31, 2024 | -63.66% |
| Sep 30, 2024 | -102.81% |
| Jun 30, 2024 | -89.55% |
| Mar 31, 2024 | -137.06% |
| Dec 31, 2023 | -73.98% |
| Sep 30, 2023 | -3,875.27% |
| Jun 30, 2023 | -14,708.74% |
| Mar 31, 2023 | -193.55% |
| Dec 31, 2022 | 50.40% |
| Sep 30, 2022 | -6,735.99% |
| Jun 30, 2022 | -128.13% |
| Mar 31, 2022 | -8,575.04% |
| Dec 31, 2021 | -102.34% |
| Sep 30, 2021 | -276.57% |
| Jun 30, 2021 | -29,336.13% |